NCT06074822

Brief Summary

Neuromuscular diseases are rare diseases for which significant progress has been made in the context of diagnosis thanks to advances in molecular techniques, but the intimate mechanisms of lesion formation remain poorly understood. Advances in cellular and molecular biology, the development of a few animal models, such as transgenic mice, which make it possible to mimic human pathology have made it possible to better understand the physiopathology of these diseases. However, they still do so very imperfectly and incompletely, making it even more necessary than ever to study diseased human muscle tissue to find new avenues of research or to confirm results obtained by experimentation. The purpose of this collection of tissue samples for neuro-muscular purposes is to collect such samples under the best conditions in order to promote basic and translational research on muscle diseases. This is why the CHU de Bordeaux wishes to keep the remainders of samples taken as part of the treatment to constitute a collection of biological samples and associated data kept according to quality standards and in compliance with the regulations in force.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
330mo left

Started Jun 2023

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress10%
Jun 2023Jun 2053

Study Start

First participant enrolled

June 26, 2023

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

August 17, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

October 10, 2023

Completed
29.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 25, 2053

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 25, 2053

Last Updated

October 10, 2023

Status Verified

August 1, 2023

Enrollment Period

30 years

First QC Date

August 17, 2023

Last Update Submit

October 5, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Constitution of a biocollection

    Collection of leftover frozen neuromuscular biopsy samples from patients taken as part of their health care at the Bordeaux University Hospital for neuromuscular disease.

    30 years

Study Arms (1)

Constitution of biocollection

Collection of remains of neuromuscular biopsy samples (nerve and muscles)

Other: Residual neuromuscular biopsy

Interventions

recovery of residual neuromuscular biopsy (nerve ans muscle)

Constitution of biocollection

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients with neuromuscular symptoms.

You may qualify if:

  • Patients treated at Bordeaux University Hospital (neurology services, neuropediatrics), rheumatology, medical genetics for suspected neuromuscular disease.
  • Men and women are affected, adults and minors.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Université Hospital, Bordeaux

Bordeaux, 33000, France

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

collection of remains of neuromuscular biopsy samples (nerve and muscles)

MeSH Terms

Conditions

Neuromuscular Diseases

Condition Hierarchy (Ancestors)

Nervous System Diseases

Study Officials

  • Marie Laure NEGRIER, Pr

    Université Hospital, Bordeaux

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 17, 2023

First Posted

October 10, 2023

Study Start

June 26, 2023

Primary Completion (Estimated)

June 25, 2053

Study Completion (Estimated)

June 25, 2053

Last Updated

October 10, 2023

Record last verified: 2023-08

Locations